Tango Therapeutics/$TNGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
- Ticker
- $TNGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 137
- Headquarters
- Boston, United States
- Website
- www.tangotx.com
TNGX Metrics
BasicAdvanced
$3.9B
-
-$0.91
1.15
-
Price and volume
Market cap
$3.9B
Beta
1.15
52-week high
$34.39
52-week low
$7.37
Average daily volume
4.2M
Financial strength
Current ratio
50.824
Quick ratio
49.953
Long term debt to equity
0.028
Total debt to equity
0.031
Profitability
EBITDA (TTM)
-134.425
Gross margin (TTM)
-148.37%
Net profit margin (TTM)
-229.92%
Operating margin (TTM)
-253.38%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-12.99%
Return on equity (TTM)
-21.34%
Valuation
Price to revenue (TTM)
58.236
Price to book
3.81
Price to tangible book (TTM)
3.81
Price to free cash flow (TTM)
-21.721
Free cash flow yield (TTM)
-4.60%
Free cash flow per share (TTM)
-1.067
Growth
Revenue change (TTM)
121.48%
Earnings per share change (TTM)
-30.79%
3-year revenue growth (CAGR)
16.89%
3-year earnings per share growth (CAGR)
-8.98%
What the Analysts think about TNGX
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
Analyst projections of the future price of Tango Therapeutics stock.
Bulls say / Bears say
Vopimetostat plus daraxonrasib produced an 82% response rate and an 88% nine-month progression-free survival rate in 22 evaluable patients with previously treated pancreatic cancer. The early results are striking and all seven responses unconfirmed at the data cutoff were later confirmed, according to Tango. (Tango Therapeutics, Inc.)
A second combination, with zoldonrasib, showed a 54% response rate and 61% nine-month progression-free survival in 35 evaluable patients. This provides another encouraging clinical signal for Tango’s PRMT5 combination approach, beyond the daraxonrasib regimen. (Tango Therapeutics, Inc.)
Tango reported $1.0 billion in cash, cash equivalents and marketable securities at the end of June 2026, which it expects to fund its current operating plan. That gives the company substantial financial capacity to advance its trials without an immediate need to raise more capital. (Tango Therapeutics, Inc.)
The headline pancreatic-cancer result comes from an early Phase 1/2 study with only 22 evaluable patients, not a randomised comparison with standard treatment. The planned registrational trial is not expected to start until the first half of 2027, leaving the benefit versus current care unproven for now. (Tango Therapeutics, Inc.)
The higher vopimetostat dose with daraxonrasib was not well tolerated: three dose-limiting toxicities occurred in two of just four safety-evaluable patients. Even at the lower dose, 40% had a Grade 3 treatment-related adverse event, which could constrain dosing or use. (Tango Therapeutics, Inc.)
Tango’s June 2026 equity offering raised capital by issuing 18.2 million shares and pre-funded warrants for about 1.8 million more shares. The financing strengthened its balance sheet but diluted existing shareholders. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
TNGX Financial Performance
Revenues and expenses
TNGX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TNGX News
AllArticlesVideos
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
MarketBeat2 weeks ago
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Benzinga2 weeks ago
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Investors Business Daily2 weeks ago
Funds containing TNGX
Fund name | Fund size | $TNGX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.24% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.24% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.10% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.